Laurus Labs Reports 126% Profit Rise in Q2, Acquires Stake in Galenvs Sciences
Laurus Labs reported a 126% rise in Q2 FY27 net profit to ₹441 crore, with revenue increasing 33% to ₹2,206 crore. The CDMO division led growth, posting a 75% revenue increase to ₹904 crore, while the affordable medicines segment grew 15%. EBITDA rose 78% to ₹762 crore, with margins expanding to 34.5%. The company also announced acquiring a 60% stake in Canada-based Galenvs Sciences to enhance oligonucleotide capabilities and strengthen its CDMO offerings.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (76/100). Lens Score 37/100.
Outlets measured: moneycontrol, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 29 Oct, 11:12 am. Other outlets followed.